Diadema Partners LP
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Diadema Partners LP reported 46 stock positions worth $160.8 million. Its top holding was Soleno Therapeutics (SLNO) at 14.8% of the portfolio, followed by Amgen (AMGN, 9.0%) and TG Therapeutics (TGTX, 8.3%). Compared with Q1 2025, it opened 17 new positions, sold out of 14, added to 16 and reduced 11. The biggest buy was Soleno Therapeutics (SLNO, shares +206%) and the biggest sale Regeneron Pharmaceuticals (REGN, shares −81%).
- Most Recent 13F
- Q2 2026
- Location
- MORRISTOWN, NJ
- CIK
- 0002026172
- Portfolio Value
- $160.8M (Q2 2025)
- SEC Filing
- 0001892688-25-000149 ↗ filed Aug 14, 2025
Holdings Value
Holdings 46 stocks · $160.8M
| SLNO Soleno Therapeutics Inc. | 14.80% | 284,152 | $23.8M | Add +205.5% |
| AMGN Amgen Inc. | 9.04% | 52,100 | $14.5M | New |
| TGTX TG Therapeutics Inc. | 8.31% | 371,448 | $13.4M | Add +78.7% |
| NBIX Neurocrine Biosciences Inc. | 7.35% | 94,042 | $11.8M | Add +51.1% |
| LLY Eli Lilly & Co. | 7.18% | 14,816 | $11.5M | Reduce -23.2% |
| JAZZ Jazz Pharmaceuticals PLC | 6.89% | 104,473 | $11.1M | Add +19.8% |
| BMRN Biomarin Pharmaceutical Inc. | 6.59% | 192,877 | $10.6M | Add +264.8% |
| PCVX Vaxcyte Inc. | 4.01% | 198,285 | $6.4M | Add +114.6% |
| VKTX Viking Therapeutics Inc. | 3.25% | 197,468 | $5.2M | Add +89.7% |
| VRTX Vertex Pharmaceuticals Inc. | 2.77% | 10,000 | $4.5M | New |
| PTGX Protagonist Therapeutics Inc. | 2.62% | 76,185 | $4.2M | New |
| GILD Gilead Sciences Inc. | 2.07% | 30,000 | $3.3M | New |
| ARGX Argenx SE - ADR | 2.05% | 5,974 | $3.3M | Reduce -51.4% |
| IMCR Immunocore Holdings PLC-ADR | 2.04% | 104,384 | $3.3M | Add +7.6% |
| REGN Regeneron Pharmaceuticals | 1.83% | 5,607 | $2.9M | Reduce -81.2% |
| RVMD Revolution Medicines Inc. | 1.81% | 79,079 | $2.9M | New |
| COGT Cogent Biosciences Inc. | 1.75% | 392,213 | $2.8M | No change |
| SRRK Scholar Rock Holding Corp. | 1.39% | 62,926 | $2.2M | Add +8.6% |
| ITOS Iteos Therapeutics Inc. | 1.28% | 206,200 | $2.1M | New |
| URGN Urogen Pharma Ltd. | 1.28% | 150,000 | $2.1M | Add +96.8% |
| RARE Ultragenyx Pharmaceutical Inc. | 1.22% | 53,985 | $2.0M | New |
| VRDN Viridian Therapeutics Inc. | 1.06% | 122,061 | $1.7M | Reduce -24.7% |
| MRK Merck & Co. Inc. | 0.98% | 20,000 | $1.6M | New |
| PCRX Pacira Biosciences Inc. | 0.88% | 58,926 | $1.4M | Add +51.4% |
| OLMA Olema Pharmaceuticals Inc. | 0.67% | 253,657 | $1.1M | Add +153.7% |
| REVIVA PHARMACEUTCLS HLDGS I | 0.65% | 2,735,457 | $1.0M | Add +320.4% |
| MIND MEDICINE MINDMED INC | 0.64% | 158,536 | $1.0M | New |
| TRVI Trevi Therapeutics Inc. | 0.63% | 185,830 | $1.0M | Add +3.2% |
| TERN Terns Pharmaceuticals Inc. | 0.60% | 259,852 | $969K | Add +363.2% |
| ETNB 89BIO Inc. | 0.60% | 98,382 | $966K | Reduce -57.5% |
| CLYM Climb Bio Inc. | 0.54% | 702,135 | $871K | Add +4.8% |
| SCPH Scpharmaceuticals Inc. | 0.52% | 217,623 | $829K | New |
| VTGN Vistagen Therapeutics Inc. | 0.50% | 403,922 | $808K | Reduce -28.6% |
| ARVN Arvinas Inc. | 0.44% | 96,455 | $710K | New |
| APGE Apogee Therapeutics Inc. | 0.29% | 10,572 | $459K | Reduce -73.6% |
| PHAT Phathom Pharmaceuticals Inc. | 0.24% | 40,294 | $386K | New |
| NUVL Nuvalent Inc. Class A | 0.24% | 5,000 | $382K | New |
| ALEC Alector Inc. | 0.23% | 266,023 | $372K | Reduce -41.7% |
| PRQR Proqr Therapeutics NV | 0.20% | 157,694 | $322K | Reduce -24.1% |
| REPL Replimune Group Inc. | 0.19% | 32,483 | $302K | Reduce -56.4% |
| ELDN Eledon Pharmaceuticals Inc. | 0.11% | 64,613 | $175K | No change |
| RLAY Relay Therapeutics Inc. | 0.09% | 43,616 | $151K | Reduce -89.8% |
| ELEV Elevation Oncology Inc. | 0.08% | 362,935 | $133K | New |
| PRTCY Puretech Health PLC - ADR | 0.08% | 7,324 | $126K | New |
| SMMT Summit Therapeutics Inc. | 0.01% | 932 | $20K | New |
| ZLAB Zai Lab Ltd.-ADR | 0.01% | 3,785 | $13K | New |
Options reported separately and not counted above: AMGN puts ($17.3M), LLY puts ($16.1M), XBI calls ($8.3M), RARE calls ($7.9M), LLY calls ($7.8M), RVMD calls ($7.4M), CORT puts ($7.4M), NVO calls ($6.9M), APGE calls ($6.8M), BBIO calls ($5.7M), CRSP calls ($5.4M), JAZZ calls ($5.3M), and 37 more.
Portfolio Sells Q1 2025 → Q2 2025
| REGN Regeneron Pharmaceuticals | Reduce -81.2% | 1.83% | −13.29 |
| LLY Eli Lilly & Co. | Reduce -23.2% | 7.18% | −5.56 |
| ARGX Argenx SE - ADR | Reduce -51.4% | 2.05% | −3.69 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −2.83 |
| RYTM Rhythm Pharmaceuticals Inc. | Sold out | 0.00% | −2.12 |
| SWTX Springworks Therapeutics Inc. | Sold out | 0.00% | −2.12 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −1.89 |
| NVO Novo-Nordisk A/S-Spons ADR | Sold out | 0.00% | −1.34 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −1.25 |
| SAGE Sage Therapeutics Inc. | Sold out | 0.00% | −1.17 |
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −1.04 |
| APGE Apogee Therapeutics Inc. | Reduce -73.6% | 0.29% | −0.91 |
| RLAY Relay Therapeutics Inc. | Reduce -89.8% | 0.09% | −0.80 |
| ETNB 89BIO Inc. | Reduce -57.5% | 0.60% | −0.74 |
| VRDN Viridian Therapeutics Inc. | Reduce -24.7% | 1.06% | −0.68 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.64 |
| VTGN Vistagen Therapeutics Inc. | Reduce -28.6% | 0.50% | −0.63 |
| REPL Replimune Group Inc. | Reduce -56.4% | 0.19% | −0.39 |
| QURE Uniqure NV | Sold out | 0.00% | −0.31 |
| GOSS Gossamer Bio Inc. | Sold out | 0.00% | −0.24 |
| ALEC Alector Inc. | Reduce -41.7% | 0.23% | −0.22 |
| MREO Mereo Biopharma Group PL-ADR | Sold out | 0.00% | −0.13 |
| SGMT Sagimet Biosciences Inc. Class A | Sold out | 0.00% | −0.12 |
| CADL Candel Therapeutics Inc. | Sold out | 0.00% | −0.11 |
| PRQR Proqr Therapeutics NV | Reduce -24.1% | 0.20% | −0.02 |
Portfolio Buys Q1 2025 → Q2 2025
| SLNO Soleno Therapeutics Inc. | Add +205.5% | 14.80% | +9.49 |
| AMGN Amgen Inc. | New | 9.04% | +9.04 |
| BMRN Biomarin Pharmaceutical Inc. | Add +264.8% | 6.59% | +3.60 |
| VRTX Vertex Pharmaceuticals Inc. | New | 2.77% | +2.77 |
| PTGX Protagonist Therapeutics Inc. | New | 2.62% | +2.62 |
| GILD Gilead Sciences Inc. | New | 2.07% | +2.07 |
| NBIX Neurocrine Biosciences Inc. | Add +51.1% | 7.35% | +1.85 |
| RVMD Revolution Medicines Inc. | New | 1.81% | +1.81 |
| TGTX TG Therapeutics Inc. | Add +78.7% | 8.31% | +1.76 |
| ITOS Iteos Therapeutics Inc. | New | 1.28% | +1.28 |
| VKTX Viking Therapeutics Inc. | Add +89.7% | 3.25% | +1.24 |
| RARE Ultragenyx Pharmaceutical Inc. | New | 1.22% | +1.22 |
| PCVX Vaxcyte Inc. | Add +114.6% | 4.01% | +1.22 |
| MRK Merck & Co. Inc. | New | 0.98% | +0.98 |
| MIND MEDICINE MINDMED INC | New | 0.64% | +0.64 |
| URGN Urogen Pharma Ltd. | Add +96.8% | 1.28% | +0.60 |
| SCPH Scpharmaceuticals Inc. | New | 0.52% | +0.52 |
| TERN Terns Pharmaceuticals Inc. | Add +363.2% | 0.60% | +0.48 |
| ARVN Arvinas Inc. | New | 0.44% | +0.44 |
| OLMA Olema Pharmaceuticals Inc. | Add +153.7% | 0.67% | +0.37 |
| PHAT Phathom Pharmaceuticals Inc. | New | 0.24% | +0.24 |
| NUVL Nuvalent Inc. Class A | New | 0.24% | +0.24 |
| REVIVA PHARMACEUTCLS HLDGS I | Add +320.4% | 0.65% | +0.15 |
| PCRX Pacira Biosciences Inc. | Add +51.4% | 0.88% | +0.10 |
| ELEV Elevation Oncology Inc. | New | 0.08% | +0.08 |
| PRTCY Puretech Health PLC - ADR | New | 0.08% | +0.08 |
| SMMT Summit Therapeutics Inc. | New | 0.01% | +0.01 |
| ZLAB Zai Lab Ltd.-ADR | New | 0.01% | +0.01 |
| SRRK Scholar Rock Holding Corp. | Add +8.6% | 1.39% | −0.10 |
| CLYM Climb Bio Inc. | Add +4.8% | 0.54% | −0.11 |
| IMCR Immunocore Holdings PLC-ADR | Add +7.6% | 2.04% | −0.26 |
| TRVI Trevi Therapeutics Inc. | Add +3.2% | 0.63% | −0.27 |
| JAZZ Jazz Pharmaceuticals PLC | Add +19.8% | 6.89% | −1.76 |
Options Activity Q1 2025 → Q2 2025
| AMGN Amgen Inc. | call | Sold out | 103,300 | $32.2Mbefore exit |
| AMGN Amgen Inc. | put | Add +19.2% | 62,100 | $17.3M |
| SLNO Soleno Therapeutics Inc. | call | Sold out | 219,400 | $15.7Mbefore exit |
| SLNO Soleno Therapeutics Inc. | put | Sold out | 217,000 | $15.5Mbefore exit |
| REGN Regeneron Pharmaceuticals | put | Sold out | 20,000 | $12.7Mbefore exit |
| NVO Novo-Nordisk A/S-Spons ADR | put | Sold out | 124,600 | $8.7Mbefore exit |
| XBI SS SPDR S&P Biotech ETF | call | New | 100,000 | $8.3M |
| RARE Ultragenyx Pharmaceutical Inc. | call | Add +85.5% | 217,000 | $7.9M |
| RVMD Revolution Medicines Inc. | call | New | 200,000 | $7.4M |
| CORT Corcept Therapeutics Inc. | put | Reduce -33.3% | 100,200 | $7.4M |
| NVO Novo-Nordisk A/S-Spons ADR | call | Reduce -8.0% | 100,000 | $6.9M |
| APGE Apogee Therapeutics Inc. | call | Add +23.8% | 156,300 | $6.8M |
| ALNY Alnylam Pharmaceuticals Inc. | put | Sold out | 20,000 | $5.4Mbefore exit |
| JAZZ Jazz Pharmaceuticals PLC | call | Reduce -29.4% | 50,000 | $5.3M |
| SPRY Ars Pharmaceuticals Inc. | call | New | 280,700 | $4.9M |
| ALT Altimmune Inc. | call | Add +201.6% | 1,262,900 | $4.9M |
| PFE Pfizer Inc. | call | Reduce -77.8% | 200,000 | $4.8M |
| CORT Corcept Therapeutics Inc. | call | Sold out | 40,000 | $4.6Mbefore exit |
| AGIO Agios Pharmaceuticals Inc. | call | Add +2.0% | 122,100 | $4.1M |
| MREO Mereo Biopharma Group PL-ADR | call | Add +155.8% | 1,317,600 | $3.6M |
| MRNA Moderna Inc. | call | Add +96.0% | 102,100 | $2.8M |
| ANAB Anaptysbio Inc. | put | Sold out | 117,300 | $2.2Mbefore exit |
| EWTX Edgewise Therapeutics Inc. | call | Sold out | 98,200 | $2.2Mbefore exit |
| MLTX Moonlake Immunotherapeutics | put | New | 41,300 | $1.9M |
| PCVX Vaxcyte Inc. | put | Sold out | 51,600 | $1.9Mbefore exit |
| ACAD Acadia Pharmaceuticals Inc. | call | New | 88,900 | $1.9M |
| SCPH Scpharmaceuticals Inc. | call | New | 486,500 | $1.9M |
| ANAB Anaptysbio Inc. | call | Sold out | 96,800 | $1.8Mbefore exit |
| SMMT Summit Therapeutics Inc. | call | Add +202.4% | 74,700 | $1.6M |
| REVIVA PHARMACEUTCLS HLDGS I | call | New | 4,000,000 | $1.5M |
| KROS Keros Therapeutics Inc. | call | Sold out | 147,100 | $1.5Mbefore exit |
| QURE Uniqure NV | call | Reduce -32.5% | 104,100 | $1.5M |
| BHVN Biohaven Ltd. | call | New | 100,000 | $1.4M |
| VKTX Viking Therapeutics Inc. | call | Sold out | 50,000 | $1.2Mbefore exit |
| KALV Kalvista Pharmaceuticals Inc. | call | Sold out | 103,300 | $1.2Mbefore exit |
| SMMT Summit Therapeutics Inc. | put | New | 50,000 | $1.1M |
| CAPR Capricor Therapeutics Inc. | put | New | 106,600 | $1.1M |
| BMEA Biomea Fusion Inc. | call | New | 568,900 | $1.0M |
| TNGX Tango Therapeutics Inc. | call | New | 200,000 | $1.0M |
| SLS Sellas Life Sciences Group I | call | New | 400,000 | $876K |
| KROS Keros Therapeutics Inc. | put | Sold out | 65,800 | $671Kbefore exit |
| ALT Altimmune Inc. | put | New | 171,400 | $663K |
| ATYR Atyr Pharma Inc. | call | Add +135.3% | 128,700 | $653K |
| PRTA Prothena Corp. PLC | call | New | 100,000 | $607K |
| EOLS Evolus Inc. | put | Sold out | 50,000 | $602Kbefore exit |
| TERN Terns Pharmaceuticals Inc. | call | New | 160,900 | $600K |
| VERV Verve Therapeutics Inc. | call | Sold out | 116,900 | $534Kbefore exit |
| FLNA Filana Therapeutics Inc. | call | Sold out | 300,000 | $450Kbefore exit |
| ATYR Atyr Pharma Inc. | put | Add +545.8% | 76,200 | $386K |
| CMPX Compass Therapeutics Inc. | call | Sold out | 200,000 | $380Kbefore exit |
Showing the first 50 of 60.
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 77 | $264.6M | UTHR, RVMD, ABVX, COGT, BMRN |
| Q1 2026 | 86 | $242.2M | BRIDGEBIO PHARMA INC (BBIO 1.75 03/01/31), VKTX, UTHR, JNJ, COGT |
| Q4 2025 | 73 | $167.9M | TERN, JNJ, VKTX, ABVX, BMRN |
| Q3 2025 | 59 | $143.6M | REGN, SLNO, BMRN, PCVX, INDV |
| Q2 2025 | 46 | $160.8M | SLNO, AMGN, TGTX, NBIX, LLY |
| Q1 2025 | 43 | $125.1M | REGN, LLY, JAZZ, TGTX, ARGX |
| Q4 2024 | 54 | $88.7M | BMY, ABBV, TEVA, BPMC, RYTM |